NuVasive Ups Bet on Orthobiologics

Share this story with your network

Alex Lukianov, NuVasive Chair and CEO, is hoping to fill a gap in the $1 billion orthobiologics market between BMPs (bone morphogenic proteins) and commodity synthetic and allograft bone extenders.

Leave a Comment

Your email address will not be published. Required fields are marked *